Company Description
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.
The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations.
It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A.
The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy.
It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers.
The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.
| Country | United States |
| Founded | 1996 |
| IPO Date | Jul 23, 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3,040 |
| CEO | Alexander Hardy |
Contact Details
Address: 770 Lindaro Street San Rafael, California 94901 United States | |
| Phone | 415 506 6700 |
| Website | biomarin.com |
Stock Details
| Ticker Symbol | BMRN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001048477 |
| CUSIP Number | 09061G101 |
| ISIN Number | US09061G1013 |
| Employer ID | 68-0397820 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Alexander Hardy | President, Chief Executive Officer and Director |
| George Eric Davis J.D. | Executive Vice President, Chief Legal Officer, General Counsel and Secretary |
| Cristin Hubbard | Executive Vice President and Chief Commercial Officer |
| Dr. Gregory Friberg M.D. | Executive Vice President and Chief Research and Development Officer |
| Erin Burkhart | Group Vice President and Chief Accounting Officer |
| Dr. C. Greg Guyer Ph.D. | Executive Vice President and Chief Technology Officer |
| Dr. Kevin Eggan Ph.D. | Chief Scientific Officer and Senior Vice President of Research and Early Development |
| Amy Wireman | Executive Vice President and Chief People Officer |
| Dr. Ganesh Vedantham Ph.D. | Senior Vice President of Technical Development |
| Marni Kottle | Executive Vice President and Chief Corporate Affairs Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 11, 2025 | 8-K | Current Report |
| Aug 5, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 5, 2025 | 10-Q | Quarterly Report |
| Aug 4, 2025 | 8-K | Current Report |
| Aug 1, 2025 | 8-K | Current Report |
| May 22, 2025 | 8-K | Current Report |
| May 20, 2025 | 144 | Filing |
| May 16, 2025 | SC TO-C | Filing |